Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zamtocabtagene autoleucel
- Development stage
- Phase 2
- Lead developer
- Miltenyi Biomedicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Zamtocabtagene autoleucel is an investigational autologous chimeric antigen receptor (CAR) T cell therapy developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. It is manufactured by modifying a patient’s own T cells to express a tandem CAR that targets both CD19 and CD20 antigens on the surface of malignant B-cells. This dual targeting aims to overcome resistance mechanisms seen with single-antigen-directed therapies by reducing the risk of antigen escape and subsequent relapse. The product is administered as a fresh (non-cryopreserved) infusion using an automated closed manufacturing system (CliniMACS Prodigy). Zamtocabtagene autoleucel has shown high response rates in clinical trials for patients who have failed at least two prior lines of therapy[1][4][5][8].
- Other names
- zamto-cel
02
Targets
Beyond the preview
Go deeper on zamtocabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zamtocabtagene autoleucel.